Publications by authors named "Stephan Siepmann"
Modification and Validation of the System Causability Scale Using AI-Based Therapeutic Recommendations for Urological Cancer Patients: A Basis for the Development of a Prospective Comparative Study.
Emily Rinderknecht Dominik von Winning Anton Kravchuk Christof Schäfer Marco J Schnabel Stephan Siepmann
Curr Oncol
November 2024
Article Synopsis
- The study explores the use of Large Language Models (LLMs) to enhance decision-making in urological cancer treatment, aiming to compare their recommendations with those of traditional tumor boards.
- It validates two scoring scales, the System Causability Scale (SCS) and its modified version (mSCS), showing they have strong reliability and internal consistency for future trials.
- The upcoming CONCORDIA trial will formally test LLM recommendations against multidisciplinary tumor board recommendations across 110 urological cancer scenarios.
Indoleamine 2,3-dioxygenase (IDO) has been identified as an important antimicrobial and immunoregulatory effector molecule essential for the establishment of tolerance by regulating local tryptophan (Trp) concentrations. On the other hand, the immunosuppressive capacity of IDO can have detrimental effects for the host as it can lead to deleterious alterations of the immune response by promoting tolerance to some types of tumors. To suppress this disadvantageous IDO effect, the competitive inhibitor 1-Methyl-Tryptophan (1-MT) is being tested in clinical trials.
View Article and Find Full Text PDF